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AbstrACt
Purpose To evaluate persistence and adherence of oral 
pharmacotherapy used in the treatment of overactive 
bladder (OAB) in a real-world setting.
Materials and methods Systematic literature searches 
of six electronic publication databases were performed to 
identify observational studies of patients with OAB treated 
with antimuscarinics and/or mirabegron. Studies obtaining 
persistence and adherence data from sources other than 
electronic prescription claims were excluded. Reference 
lists of identified studies and relevant systematic reviews 
were assessed to identify additional relevant studies.
results The search identified 3897 studies, of which 30 
were included. Overall, persistence ranged from 5% to 
47%. In studies reporting data for antimuscarinics and 
mirabegron (n=3), 1-year persistence was 12%–25% and 
32%–38%, respectively. Median time to discontinuation 
was <5 months for antimuscarinics (except one study 
(6.5 months)) and 5.6–7.4 months for mirabegron. The 
proportion of patients adherent at 1 year varied between 
15% and 44%. In studies reporting adherence for 
antimuscarinics and mirabegron, adherence was higher 
with mirabegron (mean medication possession ratio (MPR): 
0.59 vs 0.41–0.53; mean proportion of days covered: 0.66 
vs 0.55; and median MPR: 0.65 vs 0.19–0.49). Reported 
determinants of persistence and adherence included 
female (sex), older age group, use of extended-release 
formulation and treatment experience.
Conclusion Most patients with OAB discontinued oral 
OAB pharmacotherapy and were non-adherent 1 year after 
treatment initiation. In general, mirabegron was associated 
with greater persistence and adherence compared with 
antimuscarinics. Combined with existing clinical trial 
evidence, this real-world review merits consideration of 
mirabegron for first-line pharmacological treatment among 
patients with OAB.
PrOsPErO registration number  CRD42017059894.
IntrOduCtIOn
Overactive bladder (OAB) is defined as a 
condition with characteristic symptoms of 
urinary urgency, usually accompanied by 
frequency and nocturia, with or without 
urgency incontinence, in the absence of 
urinary tract infection (UTI) or other obvious 
pathology.1 OAB affects 11.8%–24.7% of 
adults in North America and Europe, and the 
prevalence increases with age.2 In addition to 
age, risk factors for developing OAB include 
diabetes, UTIs and obesity.3 4 
OAB symptoms are associated with a 
negative impact on health-related quality of 
life (HRQoL) and a significant economic 
burden. Indeed, bothersome OAB symptoms 
may lead to depression and anxiety, and sleep 
disturbances, which can adversely affect a 
patient’s daily, social and professional func-
tioning.5 6 While the cost of pharmaceutical 
treatment represents only a small fraction 
strengths and limitations of this study
 ► This systematic literature review includes data for 
mirabegron, which was approved in 2013 and not 
covered in previous systematic reviews examining 
persistence and adherence to overactive bladder 
(OAB) medication.
 ► Only observational database studies were included 
in this study, with the intention to provide a more ac-
curate picture of rates of adherence and persistence 
to OAB medication, which are generally lower in 
routine clinical practice compared with randomised 
clinical trials.
 ► This systematic literature review provides a global 
picture of adherence and persistence to OAB medi-
cation based on the inclusion of data from Canada, 
Czech Republic, Denmark, Germany, Norway, Spain, 
the UK and the USA.
 ► Although determinants of persistence and adher-
ence were evaluated in this study, the influence of 
other factors such as patient expectations, appropri-
ate counselling and patient satisfaction with treat-
ment could not be assessed.
 ► The definitions and calculations of persistence and 
adherence were not uniform across the literature. 
These terms were often used interchangeably, limit-
ing the ability to compare across studies.
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of the total therapy cost, the provision of containment 
products (eg, pads), treatment for clinical depression, 
nursing home stays and loss of productivity due to work 
absenteeism are the main cost drivers in OAB.7 8 For 
example, the total annual cost of OAB was estimated to 
be US$24.9 billion in the USA in 20079 and €9.7 billion 
across five European countries (Germany, Italy, Spain, 
Sweden and the UK) and Canada in 2005.8
Behavioural and lifestyle modifications are routinely 
the initial treatment strategy for OAB, and pharmaco-
therapy is recommended only if conservative manage-
ment is not effective.10 As OAB is a chronic condition, 
it is important that patients continue with treatment 
to control symptoms.11 Lack of persistence (time from 
treatment initiation to discontinuation)12 and adher-
ence (extent to which a patient acts in accordance with 
the prescribed interval and dose of a dosing regimen)12 
to medication are considered the leading causes of 
preventable morbidity in patients with chronic condi-
tions13 14; they are also associated with greater indirect 
costs.14 Studies have reported that patients compliant 
and adherent to OAB medication experienced signifi-
cantly improved urinary symptoms and HRQoL 
compared with patients who were non-persistent.15 16 
Although antimuscarinics are the current mainstay of 
oral pharmacotherapy, they are often associated with 
bothersome anticholinergic side effects, such as dry 
mouth and constipation; tolerability is one of the most 
common reasons for treatment discontinuation.11 17–20 
In a systematic review of antimuscarinic treatment in 
patients with OAB, rates of discontinuation at 12 weeks 
ranged from 4% to 31% in clinical trials and 43%–83% 
in medical claims databases.19
The other class of oral pharmacotherapy approved for 
the treatment of OAB is β3-adrenergic receptor agonists. 
Mirabegron is currently the only commercially available 
agent of this class licensed in countries across Europe, 
North America and Asia.21–23 Due to mirabegron’s mech-
anism of action, the incidence of side effects typically 
reported with antimuscarinic treatment are low with 
mirabegron and generally similar to placebo,24 which 
may translate into better treatment persistence.25 26 In 
addition, results of a recent economic analysis found that 
increased persistence with mirabegron treatment versus 
antimuscarinics was associated with reduced healthcare 
resource use and work hours lost, resulting in lower total 
costs.27
In general, rates of persistence and adherence with anti-
muscarinics and mirabegron are typically lower in routine 
clinical practice compared with interventional clinical 
trials.11 28 To help identify factors affecting long-term 
persistence and adherence to OAB pharmacotherapy, 
a contemporary, comprehensive review of real-world 
evidence is needed. As mirabegron was a relatively new 
OAB treatment, it was not included in previous systematic 
reviews. Therefore, the current analysis aims to systemat-
ically review prospective and retrospective observational 
database studies conducted with antimuscarinics and/or 
mirabegron to determine the rates and determinants of 
persistence and adherence.
MEthOds
This systematic literature review (SLR) was conducted in 
accordance with guidelines for the Meta-analysis of Obser-
vational Studies in Epidemiology.29 The protocol for 
the review was registered a priori with the International 
Prospective Register of Systematic Reviews (registered 
18 January 2017 with PROSPERO CRD42017059894).
Searches were performed on 27 April 2017 via the 
following electronic databases: Allied and Complemen-
tary Medicine Database; Cumulative Index to Nursing 
and Allied Health Literature; MEDLINE; Database of 
Abstracts of Reviews of Effects; Health Technology Assess-
ment database; and the Centre for Reviews and Dissem-
ination database. The search terms were persisten* OR 
adheren* OR complian* OR discont* OR tolera* OR 
utili* OR database (Title), AND ‘bladder’ OR ‘overactive 
bladder’ OR ‘OAB’ OR urin* OR incontinen* (Title), 
OR oxybutynin OR tolterodine OR fesoterodine OR 
trospium OR darifenacin OR solifenacin OR propiverine 
OR imidafenacin OR mirabegron OR flavoxate OR hyos-
cyamin* OR anticholinerg* OR antimuscarin* (Title).
All search results were exported into EndNote Web 
(Thomas Reuter, Califonia, USA) bibliography software 
and duplicates removed electronically and manually. 
The full electronic search strategy is outlined in the 
online supplementary information.
Inclusion and exclusion criteria
Inclusion criteria were: prospective and retrospective 
observational database studies investigating persistence 
and adherence to oral medication for the treatment of 
OAB in adults, conducted in any geographical location 
and published on any date, within a peer-reviewed source. 
Exclusion criteria were: abstract unavailable; studies 
not yet fully completed; randomised controlled trials 
(RCTs); systematic reviews; narrative literature reviews; 
conference papers; single case studies/reports; studies 
investigating OAB medication among only healthy, 
asymptomatic participants; studies from which oral-only 
OAB persistence/adherence results cannot be isolated 
from other results (ie, transdermal patches); and studies 
containing patients aged <18 years (where the data 
pertaining to these patients could not be removed from 
the results) and studies not published in English. Popu-
lations with lower urinary tract symptoms due to stress 
incontinence and benign prostatic hyperplasia were also 
excluded.
study selection
Duplicates were removed and title and abstract screen-
ings were performed by two independent researchers (PS 
and GY). Full-text articles were obtained and studies were 
excluded if they did not meet the inclusion criteria.30 Any 
disagreement in study selection was to be resolved through 
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discussion and consultation with another member of the 
project team (FF) where necessary. During screening, 
open-label extension studies of RCTs were excluded 
as the trial designs were unlikely to reflect a real-world 
setting. Studies using data from hospital records, in addi-
tion to large-scale databases, were included provided 
that persistence and adherence data were determined 
from prescription claims data rather than extracted from 
supplemental patient interviews, patient-supplied pill 
counts or subjective questionnaires. The literature search 
was supplemented by screening for potential additional 
relevant studies identified from the reference lists of 
eligible articles.
data extraction
Parameters that may affect persistence or adherence were 
collected, including patient characteristics (age and sex), 
interventions (initial (index) OAB drug and formula-
tion) and comorbidities. The definitions, outcomes and 
determinants of treatment persistence and adherence 
were also collected, where reported. The extracted data 
were evaluated by one researcher and verified by a second 
researcher.
data analysis
A descriptive analysis of extracted results is presented. No 
meta-analysis was planned due to the expected heteroge-
neity of reporting methodologies and data across studies.
Patient and public involvement
Patients were not directly involved in the conduct of this 
study.
rEsults
brief overview of studies
Overall, 3897 articles were identified from the literature 
search; 3614 were screened for title/abstract and 75 were 
assessed for eligibility (figure 1). Thirty articles were 
included in the SLR (see online supplementary table 1), 
including three identified from reference lists.31–33 The 
articles described the findings of 28 independent studies. 
There was nil disagreement between the two indepen-
dent researchers (PS, GY) during the screening process.
The data were collected from patients treated in 
Europe (12 studies) and North America (18 studies) 
(see online supplementary table 1) and were included 
in the analysis. The number of participants included in 
the published studies ranged from 377 to 103 250. Where 
stated, the mean age of the participants ranged from 44 
to 80 years and the duration of follow-up ranged from 
6 months to 7 years. Prescribed antimuscarinic interven-
tions for patients with OAB included darifenacin, fesoter-
odine, flavoxate, hyoscyamine, imipramine, oxybutynin, 
propiverine, solifenacin, tolterodine and trospium chlo-
ride. Mirabegron was prescribed in four studies.18 26 31 34 
Uncommon oral interventions included imipramine, a 
tricyclic antidepressant with an unknown mechanism of 
action in the context of OAB,35 and bethanechol, a musca-
rinic receptor agonist.33 The methods used to quantify 
adherence and persistence differed across the studies 
(see online supplementary table 1). In general, medica-
tion possession rate (MPR) or proportion of days covered 
(PDC) by prescription were typically used as a measure of 
adherence to a drug. Persistence was typically defined as 
the proportion of patients continuing therapy/refilling 
prescriptions for the follow-up period (without discontin-
uing the index drug or switching to other OAB drug(s)) 
and/or the median time to discontinuation (TTD).
Persistence
Overall, persistence rates decreased over time, regardless 
of agent (see online supplementary table 2).
Antimuscarinic studies
Data for persistence (or discontinuation) at approxi-
mately 6 months was available in 14 articles32 33 36–47 which 
reported data on antimuscarinics only. Yeaw et al was an 
exception due to the inclusion of bethanechol (a musca-
rinic receptor agonist), which accounted for <1.5% of the 
pharmacy claims for OAB medications.33 The proportion 
of patients persistent at 6 months was <50% except for 
the studies of Sicras-Mainar et al,42–44 where persistence 
ranged from 57% to 71%. In addition, two studies 
reported discontinuation rates of 6%–43% after 1 month 
of initial treatment.41 47
At 1 year, persistence rates for antimuscarinics 
across 19 studies ranged from around 5% up to 
47%.18 26 33–36 38 40 42 43 45–53 Median TTD was <5 months 
(30 to 128 days) for all medications across all 
studies,18 26 32 34 38 48 49 with the exception of Krhut et al40 
(6.5 months). At 2 years, over 75% of patients discon-
tinued treatment.36 38 49–51 Rates of treatment switching 
were infrequently reported, and where provided, 
were ≤17% of patients.32 37 39 48 49 51 52
Antimuscarinic and mirabegron studies
In all four studies, a greater proportion of patients 
persisted with mirabegron compared with antimusca-
rinics. In one study, persistence rates for tolterodine and 
mirabegron at 6 months were 19% and 35%, respec-
tively.31 Persistence at 1 year ranged from 8% to 25% for 
antimuscarinics and from 32% to 38% for mirabegron, as 
reported in three studies.18 26 34 Where tested inferentially, 
1 year persistence was statistically significantly greater with 
mirabegron compared with antimuscarinics (p<0.0001), 
with the exception of oxybutynin (p=0.002).18 The risk 
of discontinuing within 1 year was also greater with anti-
muscarinics compared with mirabegron (p<0.001).18 26 
Overall, mirabegron, solifenacin and fesoterodine were 
associated with the highest rates of persistence.18 26
Across the four studies, 40%–81% and 83%–96% of 
the mirabegron and antimuscarinic patient cohorts 
were treatment naïve, having received no OAB drug for 
at least 6 months prior to their first index of OAB treat-
ment.18 26 31 34 Studies typically found that treatment-naive 
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patients prescribed mirabegron or antimuscarinics had 
lower persistence than treatment-experienced patients 
prescribed the same OAB treatments. In the three studies 
that assessed persistence in treatment-experienced and 
treatment-naïve populations, persistence was higher 
with mirabegron treatment (significantly in two studies) 
compared with antimuscarinics.18 26 31
Median TTD in the overall study populations was 
longer with mirabegron (5.6–7.4 months) compared with 
the assessed antimuscarinics (1.0–3.6 months).18 26 31 34
Adherence
Adherence rates to all OAB medications reduced over time 
in all studies and varied across studies (see online supple-
mentary table 2).
Antimuscarinic studies
At 1 year, the proportion of adherent patients varied 
between 1%47 and 36%,48 across those studies that 
provided these data. Few studies reported adherence 
beyond 1 year. However, Sears et al reported that 34% 
Figure 1 Search strategy and selection of studies presented in the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) flow diagram. *Studies were excluded for the following reasons: outcome measure(s) of persistence 
and/or adherence, relevant to this systematic review (such as medication possession rate, proportion of days covered, 
discontinuation rate), were not presented within the full text of the article (n=17); adherence/persistence data were drawn 
from surveys, interviews or self-reports (n=13); cohort contained a portion of patients under 18 years of age (who could not 
be removed or isolated from results/data) (n=7); participants had prior awareness/knowledge of partaking in a study related to 
overactive bladder (OAB) medication (ie, open-label extension to a study or prior written consent) (n=6); a full article text was 
not available (ie, only a conference abstract) or the full text was not in English (n=4); or non-oral OAB medications were included 
within the presented results (and could not be removed or isolated from results/data) (n=1). §Three of these studies were 
identified by reviewing reference lists of included studies and relevant systematic literature reviews.
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of patients were adherent at the end of 3 years,53 which 
was comparable to the adherence rates reported by some 
other studies at just 1 year.48 52
Antimuscarinic and mirabegron studies
In the three studies, adherence at 1 year was significantly 
higher in patients receiving mirabegron compared with 
antimuscarinics (mean MPR: 0.59 vs 0.41 to 0.53; mean 
PDC: 0.66 vs 0.55; and median MPR: 0.65 vs 0.19 to 
0.49).18 26 34 The proportion of patients adherent at 1 year 
was also greater with mirabegron compared with anti-
muscarinics (mean MPR ≥0.80: 43% vs 22%–35%; mean 
PDC ≥0.80: 44% vs 31%).18 26 Within treatment-naive 
patients specifically, adherence was greater with mirabe-
gron compared with antimuscarinics, 0.59 vs 0.39–0.51, 
p values 0.02 to <0.0001).18
determinants of persistence and adherence
Determinants of persistence and adherence were 
reported in 24 of the 30 studies. As expected, most 
studies reported medication type as a determinant of 
persistence/adherence (figure 2; see online supple-
mentary table 2). In general, persistence and adherence 
were higher in: older patients compared with younger 
patients26 31 32 35–39 46 48–50 52 54 55; female patients compared 
with their male counterparts,32 35 36 39 50 54 55 except in 
one study53; patients receiving extended-release (ER) 
formulations compared with immediate-release formu-
lations48 49; and treated patients compared with treat-
ment naive patients (or untreated in the preindex period 
(6 months or 1 year)).18 26 36 Comorbidities, including 
diabetes, Parkinson’s disease, epilepsy, dementia, 
multiple sclerosis and hypertension, were correlated with 
increased treatment persistence and adherence50 54 55; 
exceptions were chronic obstructive pulmonary disease 
and migraine.50 55
Other reported determinants of favourable persistence 
and adherence included higher treatment doses36; low 
daily quantity of tablets37; absence of UTI; higher-base-
line OAB costs39; treatment by urologists versus gynaecol-
ogists/general practitioners; the absence of side effects 
(headache, stomach upset and glaucoma)50; White versus 
Black, Hispanic and Asian patients and patients of other 
ethnicities35 47; lower medication copayment35; and use of 
fewer medications.47
dIsCussIOn
This systematic review provides an overview of persistence 
and adherence with oral pharmacotherapies used to treat 
patients with OAB in real-life clinical practice. A wealth 
of data were collected from 30 articles, which described 
28 observational studies performed in Europe and North 
America totalling over 500 000 patients. A number of key 
findings were identified, including greater persistence 
and adherence with mirabegron versus antimusca-
rinics,18 26 31 34 in women versus men,32 35 39 54 55 in older 
versus younger patients,26 31 32 35–39 46 48–50 52 54 55 and in 
previously treated versus untreated patients.18 26 36
Across the studies, persistence appeared to reduce very 
quickly after initiation of treatment for all OAB therapies, 
with low rates (<50%) already evident at 1 month.31 41 47 
Longer follow-up periods showed that large proportions 
Figure 2 Frequency for reported determinants of discontinuation. *In one study, the relationship was not statistically 
significant. **Includes dose, formulation, race, prior infection, financial burden, prescriber profession, side effects, medication 
copayment and polypharmacy.
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of patients discontinued treatment by 1 year (62%–
100%)18 26 33 38 45–47 49 50 54 and by the end of 3 years, less 
than 10% of patients continued on any antimuscarinic.49 
These steep reductions in rates of persistence over time 
were mirrored by the reported adherence rates.
The chronic nature of OAB means that consistent 
and long-term use of medication is essential to manage 
OAB symptoms and improve health outcomes. It is there-
fore important for patients to receive a first-line treat-
ment that has a good efficacy-tolerability profile and 
evidence of favourable persistence and adherence versus 
other treatment options. Among the antimuscarinics, 
solifenacin and fesoterodine were generally associated 
with better persistence and adherence.18 26 43 52 In studies 
that assessed both mirabegron and antimuscarinics, 
persistence in the mirabegron cohorts, including the 
treatment-naive populations, was statistically significantly 
greater (p<0.001).18 26 31 Due to the recommended treat-
ment sequence for OAB,10 56 the majority of patients that 
receive mirabegron are treatment-experienced; however, 
these studies suggest a benefit of mirabegron treatment 
regardless of treatment status. Adherence to mirabegron 
was also greater; however, mean/median MPR values 
in the overall mirabegron populations did not indicate 
medication adherence (MPR/PDC<0.80). Although 
these studies did not directly assess the reason(s) for an 
observed difference in persistence and adherence with 
mirabegron versus antimuscarinics, proposed reasons 
include lower rates of bothersome anticholinergic adverse 
events, particularly dry-mouth, and unmet expectations 
of antimuscarinic treatment.18 26 31
It is well established that poor medication persistence 
and adherence reduces the ability to achieve optimum 
clinical benefits and limits treatment success, especially 
for chronic conditions such as OAB.13 14 17 46 The unwill-
ingness of patients to continue to take long-term treat-
ment has been observed across many chronic conditions, 
with non-adherence to medication observed in ~50% of 
patients.13 An analysis across six chronic conditions found 
1 year persistence and adherence rates to be low for all 
conditions, and lowest for OAB medications (antimusca-
rinics),33 suggesting an unmet treatment need. However, 
this study was performed prior to the availability of mira-
begron for use in routine clinical practice, and therefore 
an updated analysis of persistence in chronic conditions 
might be warranted.
As alluded to above, persistence and adherence to treat-
ment is expected to improve outcomes for patients with 
OAB. In two studies, better OAB treatment persistence 
and adherence were associated with improved clinical 
outcomes and HRQoL compared with patients who were 
non-persistent.15 16 These data are consistent with studies 
describing other chronic diseases, such as diabetes and 
depression, where good adherence resulted in improved 
health outcomes14 57 as well as reduced complications and 
disability, and improved HRQoL and life expectancy.58 
Moreover, greater persistence and adherence to treatment 
for OAB is associated with significantly lower medical, sick 
leave and short-term disability costs.35 Indeed, economic 
models based on real-world inputs suggest that improved 
persistence with mirabegron translates into benefits of 
reduced healthcare resource use, and lower direct and 
indirect costs of treatment compared with antimusca-
rinics.27 59 Additionally, mirabegron is reported to be 
cost-effective versus six antimuscarinics from commer-
cial and medicare perspectives in the USA, due to fewer 
projected adverse events and comorbidities, and data 
suggesting better persistence.60
Independent variables for treatment discontinuation 
were studied by at least half of the papers included in our 
literature review, of which sex, age, comorbidities and 
previous experience of OAB medications were shown to 
be important factors in more than two studies. Only six 
studies reported switch rates and although these were 
low, the treatment strategy of cycling antimuscarinic 
agents in patients who do not achieve symptom relief is 
common in clinical practice. Yet, recent analysis of real-
world data suggests that switching antimuscarinics may 
provide suboptimal care.51 In contrast, switching to mira-
begron from antimuscarinic therapy has proven benefi-
cial in over 50% of patients with OAB in an observational 
study.61
This review represents a large pooled analysis of real-world 
data for persistence and adherence to oral OAB medication 
across different geographical locations (Canada, Czech 
Republic, Denmark, Germany, Norway, Spain, the UK 
and the USA); however, there were no identifiable trends 
between data and countries. The definitions and calcula-
tions of persistence and adherence were not uniform across 
the literature and the terms were often used interchange-
ably. This lack of consistency led to some limitations on 
the ability to compare across studies. Other limitations to 
performing cross-study comparisons or pooled analyses in 
this SLR include differences in the individual study popu-
lations and/or study designs, resulting in considerable 
variations between data. For example, the median TTD for 
oxybutynin ER and tolterodine ER were determined to be 
5.1 and 5.5 months, respectively, by one study,49 but only 60 
and 56 days, respectively, by another study.18
Furthermore, it is very difficult to capture the specific 
reasons for treatment discontinuation from prescrip-
tion-driven or medical claim data rather than patient-de-
rived data.18 The current review excluded data from RCTs 
to better reflect patient behaviour in the general OAB 
population in real-life clinical practice.11 Only one paper 
included in our review reported that antimuscarinic 
side effects were significantly associated with discontin-
uation,50 despite reports that such side effects are both-
ersome and a common reason for discontinuation of 
antimuscarinic treatment.11 19 28 Additional factors that 
could not be assessed by our study, but can influence 
persistence with treatment in OAB patients, are patient 
expectations, appropriate counselling and patient satis-
faction with treatment.11 17 28
In addition to the limitations listed above, it should 
be noted that Sicras-Mainar et al42 43 reported data on 
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the same patients (in terms of demographics and the 
time frame/geographical source). This is also the case for 
two studies published by Sicras-Mainar et al in 2013 and 
2014.62 63 Also, this SLR excluded data on non-oral phar-
macotherapies (eg, onabotulinum toxin A) and combi-
nation mirabegron plus antimuscarinic therapies, where 
additional efficacy has been reported compared with 
the monotherapies.64 Further research on persistence 
and adherence to these OAB therapies is needed to 
better evaluate current treatment options. Additional 
studies are also required to improve our understanding 
of persistence and adherence in OAB, including quali-
tative studies to examine the reasons for discontinuation 
and real-world studies to examine resource use associ-
ated with OAB medication in relation to adherence and 
persistence. As OAB is a chronic disease, clinicians should 
not only take into consideration the efficacy and side 
effects of an agent when deciding on treatment options, 
but also ensure that realistic patient expectations from 
treatment are set through patient education and coun-
selling. The patient’s lifestyle should also be considered 
as this is likely to impact adherence and persistence with 
OAB therapy.
COnClusIOns
Persistence and adherence were greater with mirabe-
gron compared with antimuscarinics, and appeared to be 
greater with solifenacin and fesoterodine compared with 
other antimuscarinics. In addition, greater persistence 
and adherence were generally observed in patients who 
were female, older, treatment-experienced and receiving 
ER formulations. Together with the efficacy and tolera-
bility data from clinical trials, real-world data examined 
in this review warrant consideration of using mirabegron 
as first-line oral pharmacotherapy for patients with OAB.
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